FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362596987> ?p ?o ?g. }

• W4362596987 endingPage "455" @default.
• W4362596987 startingPage "455" @default.
• W4362596987 abstract "Abstract Antibody drug conjugate (ADC) is a novel class of therapeutic agent which recently showed great success in both solid tumour and blood cancer. ADCs deliver potent cytotoxic payloads to tumour via cancer specific monoclonal antibodies. A few ADCs are currently evaluated in clinical trials for high grade serous ovarian cancer (HGSOC). However, most of them target FOLR1-alpha, a conventional HGSOC target which also expresses in vital organs including lungs. Thus, it is desirable to discover more specific antigen targets, and these new targets will be the foundation for the next-generation ADC for HGSOC.We propose that ovarian tumour specificity of an ADC target could contributed by three factors: 1. Lineage (e.g. fallopian tube marker FOLR1); 2. DNA amplification (e.g. ERBB2); 3. Other carcinogenesis process including epigenetic reprogramming. Then, by combining the GTEX, TCGA dataset with our own WES, long-reads RNA-sequencing and Mass spectrometry-based proteomics cohort, an array of differentially expressed genes in HGSOC tumours are identified. Out of over 50 candidates, two most promising targets are chosen for monoclonal antibodies (mAbs) production and subsequent ADC development. First, the affinity and specificity of the mAbs were confirmed by ELISA, flow cytometry and immunofluorescence. The cellular internalisation characteristics of these antibodies are confirmed by a fluorescence-based assay. Then, ADCs for these two targets are produced by conjugating monomethyl auristatin E payload to the mAbs via a cleavable linker. Finally, both ADCs show highly target-specific and sub-nanomolar cytotoxicity in model ovarian cancer cell lines. In conclusion, we identify a panel of HGSOC-specific ADC targets and develop two ADCs candidates for further pre-clinical and clinical investigations. Citation Format: Ruisi Fu, Hantao Lou, Ning Wang, Dongnan Yan, Clara Tresserras-Segura, Haonan Lu, Eric Aboagye. Development of an antibody-drug conjugate panel targeting high grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 455." @default.
• W4362596987 created "2023-04-06" @default.
• W4362596987 creator A5025605493 @default.
• W4362596987 creator A5034089378 @default.
• W4362596987 creator A5043839950 @default.
• W4362596987 creator A5054775841 @default.
• W4362596987 creator A5063076993 @default.
• W4362596987 creator A5068985602 @default.
• W4362596987 creator A5088245637 @default.
• W4362596987 date "2023-04-04" @default.
• W4362596987 modified "2023-10-18" @default.
• W4362596987 title "Abstract 455: Development of an antibody-drug conjugate panel targeting high grade serous ovarian cancer" @default.
• W4362596987 doi "https://doi.org/10.1158/1538-7445.am2023-455" @default.
• W4362596987 hasPublicationYear "2023" @default.
• W4362596987 type Work @default.
• W4362596987 citedByCount "0" @default.
• W4362596987 crossrefType "journal-article" @default.
• W4362596987 hasAuthorship W4362596987A5025605493 @default.
• W4362596987 hasAuthorship W4362596987A5034089378 @default.
• W4362596987 hasAuthorship W4362596987A5043839950 @default.
• W4362596987 hasAuthorship W4362596987A5054775841 @default.
• W4362596987 hasAuthorship W4362596987A5063076993 @default.
• W4362596987 hasAuthorship W4362596987A5068985602 @default.
• W4362596987 hasAuthorship W4362596987A5088245637 @default.
• W4362596987 hasConcept C121608353 @default.
• W4362596987 hasConcept C126322002 @default.
• W4362596987 hasConcept C142724271 @default.
• W4362596987 hasConcept C150173356 @default.
• W4362596987 hasConcept C159654299 @default.
• W4362596987 hasConcept C203014093 @default.
• W4362596987 hasConcept C2777325958 @default.
• W4362596987 hasConcept C2780427987 @default.
• W4362596987 hasConcept C502942594 @default.
• W4362596987 hasConcept C542903549 @default.
• W4362596987 hasConcept C71924100 @default.
• W4362596987 hasConcept C86803240 @default.
• W4362596987 hasConceptScore W4362596987C121608353 @default.
• W4362596987 hasConceptScore W4362596987C126322002 @default.
• W4362596987 hasConceptScore W4362596987C142724271 @default.
• W4362596987 hasConceptScore W4362596987C150173356 @default.
• W4362596987 hasConceptScore W4362596987C159654299 @default.
• W4362596987 hasConceptScore W4362596987C203014093 @default.
• W4362596987 hasConceptScore W4362596987C2777325958 @default.
• W4362596987 hasConceptScore W4362596987C2780427987 @default.
• W4362596987 hasConceptScore W4362596987C502942594 @default.
• W4362596987 hasConceptScore W4362596987C542903549 @default.
• W4362596987 hasConceptScore W4362596987C71924100 @default.
• W4362596987 hasConceptScore W4362596987C86803240 @default.
• W4362596987 hasIssue "7_Supplement" @default.
• W4362596987 hasLocation W43625969871 @default.
• W4362596987 hasOpenAccess W4362596987 @default.
• W4362596987 hasPrimaryLocation W43625969871 @default.
• W4362596987 hasRelatedWork W1591820460 @default.
• W4362596987 hasRelatedWork W2010226282 @default.
• W4362596987 hasRelatedWork W2053181077 @default.
• W4362596987 hasRelatedWork W2087126635 @default.
• W4362596987 hasRelatedWork W2130330160 @default.
• W4362596987 hasRelatedWork W2147619880 @default.
• W4362596987 hasRelatedWork W2363885141 @default.
• W4362596987 hasRelatedWork W2371164331 @default.
• W4362596987 hasRelatedWork W4239738004 @default.
• W4362596987 hasRelatedWork W4362596987 @default.
• W4362596987 hasVolume "83" @default.
• W4362596987 isParatext "false" @default.
• W4362596987 isRetracted "false" @default.
• W4362596987 workType "article" @default.